Preliminary Investigation of Uptake in PSMA Expressing Cancer, Biodistribution and Excretion of the Novel Radio Tracer [68Ga]P16-093 by PET/CT

Trial Profile

Preliminary Investigation of Uptake in PSMA Expressing Cancer, Biodistribution and Excretion of the Novel Radio Tracer [68Ga]P16-093 by PET/CT

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Gallium-68-P16-093 (Primary)
  • Indications Prostate cancer; Renal cancer
  • Focus Diagnostic use
  • Sponsors Five Eleven Pharma
  • Most Recent Events

    • 03 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 14 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top